Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Benefytt Technologies, Inc.BFYT · Entity 147002 | Director | August 21, 2020 | August 25, 2020 |
| Jackson Acquisition Co IIJACS · Entity 5885 | Director | December 09, 2024 | December 11, 2024 |
| Pediatrix Medical Group, Inc.MD · Entity 4451 | Director | May 12, 2021 | May 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Benefytt Technologies, Inc.
Report date August 21, 2020 · Filed August 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-21 transaction · row 1
1 source rowRow 1 · 2020-08-21 · Other · Disposed 91,504 · Balance 0 F1: On August 21, 2020, Daylight Beta Corp., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Daylight Beta Parent Corp., a Delaware corporation ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Benefytt Technologies, Inc., a Delaware corporation (the "Issuer"), pursuant to that certain Agreement and Plan of Merger dated July 12, 2020 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on August 21, 2020, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned and indirect subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on August 21, 2020. F2: Represents shares tendered to the Purchaser in connection with the Tender Offer. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 21, 2020, Daylight Beta Corp., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Daylight Beta Parent Corp., a Delaware corporation ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Benefytt Technologies, Inc., a Delaware corporation (the "Issuer"), pursuant to that certain Agreement and Plan of Merger dated July 12, 2020 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on August 21, 2020, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned and indirect subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on August 21, 2020.
F2: Represents shares tendered to the Purchaser in connection with the Tender Offer.
Jackson Acquisition Co II
Report date December 09, 2024 · Filed December 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-12-09 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in Issuer's Registration Statement on Form S-1 (File No. 333-282393), as amended, the Class B ordinary shares, par value $0.0001 per share, of the Issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of a qualifying initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in Issuer's Registration Statement on Form S-1 (File No. 333-282393), as amended, the Class B ordinary shares, par value $0.0001 per share, of the Issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the Issuer at the time of a qualifying initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and have no expiration date.
Pediatrix Medical Group, Inc.
Report date May 12, 2021 · Filed May 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,198 |
Reported balance
After 2021-05-12 transaction · row 1
1 source rowRow 1 · 2021-05-12 · Grant · Acquired 4,885 · Balance 29,198 F1: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2021 Filed May 14, 2021 20:20 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 4,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032709 · doc4.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,198 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 12, 2022. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 15:11 UTC | Benefytt Technologies, Inc. BFYT · Entity 147002 | OtherClass A Common Stock | 91,504 | $31.00 | $2,836,624.00 |
DisclosureSEC source: 0001567619-20-015949 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 21, 2020, Daylight Beta Corp., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Daylight Beta Parent Corp., a Delaware corporation ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Benefytt Technologies, Inc., a Delaware corporation (the "Issuer"), pursuant to that certain Agreement and Plan of Merger dated July 12, 2020 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on August 21, 2020, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned and indirect subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on August 21, 2020. F2 · kind: Represents shares tendered to the Purchaser in connection with the Tender Offer. Read SEC document |
| May 12, 2020 Filed May 14, 2020 16:22 UTC | Benefytt Technologies, Inc. BFYT · Entity 147002 | GrantClass A Common Stock | 3,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-010102 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,504 F1 · shares: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan") and are scheduled to vest 50% on May 12, 2021 and 50% on May 12, 2022, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 16:17 UTC | Benefytt Technologies, Inc. BFYT · Entity 147002 | Exercise / conversionStock Appreciation Rights · Derivative | 20,000 | $0.00 Strike: $11.73 | $0.00 |
DisclosureSEC source: 0001567619-20-005913 · doc1.xml · derivative · entry 3 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,000 shares Expires 2020-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock appreciation rights immediately prior to the expiration thereof. F3 · derivative.exercise_date: These stock-settled stock appreciation rights were granted under the Issuer's Long Term Incentive Plan and are exercisable in full. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 16:17 UTC | Benefytt Technologies, Inc. BFYT · Entity 147002 | Disposition to issuerClass A Common Stock | 8,566 | $27.39 | $234,622.74 |
DisclosureSEC source: 0001567619-20-005913 · doc1.xml · nonDerivative · entry 2 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,816 F2 · kind: Shares retained by the issuer to satisfy the exercise price of stock appreciation rights. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 16:17 UTC | Benefytt Technologies, Inc. BFYT · Entity 147002 | Exercise / conversionClass A Common Stock | 20,000 | $11.73 | $234,600.00 |
DisclosureSEC source: 0001567619-20-005913 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the exercise of stock appreciation rights immediately prior to the expiration thereof. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:04 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 4,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010327 · doc4.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,313 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest in three equal installments on March 1, 2021, March 1, 2022 and March 1, 2023. Read SEC document |
| May 14, 2019 Filed May 16, 2019 18:03 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | GrantClass A Common Stock | 3,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011450 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,382 F1 · shares: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan") and are scheduled to vest 50% on May 14, 2020 and 50% on May 14, 2021, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. Read SEC document |
| March 20, 2019 Filed Mar 20, 2019 16:12 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | PurchaseClass A Common Stock | 8,000 | $29.91 | $239,254.40 |
DisclosureSEC source: 0001567619-19-007304 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,869 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $29.8924 to 29.902, inclusive. The Reporting Person undertakes to provide Health Insurance Innovations Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:35 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 3,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010190 · doc4.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,596 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. Shares will vest in three equal installments on March 1, 2020, March 1, 2021 and March 1, 2022. Read SEC document |
| December 17, 2018 Filed Apr 10, 2019 17:30 UTC Amendment | Benefytt Technologies, Inc. HIIQ · Entity 147002 | PurchaseClass A Common Stock | 15,000 | $30.63 | $459,519.00 |
DisclosureSEC source: 0001567619-19-008676 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,869 F1 · date: This amendment is being filed to correct the reported transaction date from 12/07/2018 to 12/17/2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $29.8358 to 31.0877, inclusive. The Reporting Person undertakes to provide Health Insurance Innovations Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| December 07, 2018 Filed Dec 18, 2018 13:18 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | GrantClass A Common Stock | 15,000 | $30.63 | $459,519.00 |
DisclosureSEC source: 0001567619-18-008187 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,869 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $29.8358 to 31.0877, inclusive. The Reporting Person undertakes to provide Health Insurance Innovations Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1 · balance_after: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $29.8358 to 31.0877, inclusive. The Reporting Person undertakes to provide Health Insurance Innovations Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:41 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | GrantClass A Common Stock | 2,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024444 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,869 F1 · shares: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan") and are scheduled to vest 50% on May 15, 2019 and 50% on May 15, 2020, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. F1 · balance_after: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan") and are scheduled to vest 50% on May 15, 2019 and 50% on May 15, 2020, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. Read SEC document |
| May 04, 2018 Filed May 7, 2018 10:30 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | GrantClass A Common Stock | 3,000 | $27.00 | $81,000.00 |
DisclosureSEC source: 0001140361-18-021869 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,261 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:01 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 2,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015782 · doc4.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,897 F1 · shares: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. Shares will vest in three equal installments on March 1, 2019, March 1, 2020 and March 1, 2021. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:16 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | GrantClass A Common Stock | 1,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-025352 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,261 F1 · shares: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan"), as amended, and are scheduled to vest 50% on May 18, 2018 and 50% on May 18, 2019, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. F1 · balance_after: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan"), as amended, and are scheduled to vest 50% on May 18, 2018 and 50% on May 18, 2019, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:41 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 2,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037306 · doc4.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,547 F1 · shares: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. Shares will vest in three equal installments on June 1, 2018, June 1, 2019 and June 1, 2020. Read SEC document |
| May 18, 2017 Filed May 22, 2017 16:50 UTC | Benefytt Technologies, Inc. HIIQ · Entity 147002 | GrantClass A Common Stock | 2,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-021749 · doc1.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,895 F1 · shares: These restricted shares were granted under the Issuer's Long Term Incentive Plan ("Plan") and are scheduled to vest 50% on May 18, 2018 and May 18, 2019, subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement under the Plan. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:31 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,668 | $27.72 Strike: $27.72 | $295,663.62 |
DisclosureSEC source: 0001209191-17-012117 · doc4.xml · derivative · entry 5 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,668 shares Expires 2018-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:31 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,668 | $32.33 Strike: $32.33 | $344,843.10 |
DisclosureSEC source: 0001209191-17-012117 · doc4.xml · derivative · entry 4 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,668 shares Expires 2017-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:31 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 21,336 | $69.63 | $1,485,664.08 |
DisclosureSEC source: 0001209191-17-012117 · doc4.xml · nonDerivative · entry 3 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,255 F1 · price: The price reported in Column 4 is an weighted average price. These shares were sold in thirty-three (33) separate transactions with prices ranging from $69.4250 to $69.78 for an average weighted sales price of $69.6318. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:31 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Exercise / conversionCommon Stock | 10,668 | $27.72 | $295,663.62 |
DisclosureSEC source: 0001209191-17-012117 · doc4.xml · nonDerivative · entry 2 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:31 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Exercise / conversionCommon Stock | 10,668 | $32.33 | $344,843.10 |
DisclosureSEC source: 0001209191-17-012117 · doc4.xml · nonDerivative · entry 1 GABOS PAUL G · CIK 0001216803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.